NEWS

Vesalio announces CE Approval for new NeVa NET™, the first integrated cl...

Nashville, Tennessee - (September 1, 2022) – In further expansion of their high-performance thrombectomy portfolio, Vesalio announced CE approval for commercialization of the new NeVa NET, the first and only thrombectomy device with an integrated clot micro-filtration technology. This one-of-a-kind stent retriever combines the company’s proprietary Drop Zone technology, proven to work on all clot types, with a finely braided micro-filter net element integrated into the closed distal tip of the device.

Vesalio announces oversubscribed class A financing

Nashville, TN – (May 18, 2022) – Vesalio, an emerging leader in improving outcomes in patients with vascular occlusion, is proud to announce it has oversubscribed its Class A financing round. Solas BioVentures led the investment with participation by new and existing investors, including the recent addition of Orlando Health Ventures.

Vesalio Announces the Completion of Enrollment in Its FDA IDE Clinical S...

Nashville, TN May 11, 2022 --(  PR.com  )-- Vesalio is excited to announce the completion of patient enrollment for the CLEAR(1) FDA IDE study utilizing the NeVa™ thrombectomy platform. This is an important milestone for Vesalio to complete for entering the U.S. neurovascular market to treat patients suffering from acute ischemic stroke (AIS).

MicroVention Announces First Patient Enrolled in the STRAIT Study with t...

Aliso Viejo, CA – April 20, 2022 – MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced the successful completion of its first enrollment in a multi-center, prospective EU observational study called STRAIT, to evaluate the Safety and Performance of the BOBBY Balloon Guide Catheter for Endovascular Treatment of Acute Ischemic Stroke.

Vesalio Announces Earl Slee as New Board Observer and Senior Advisor to...

Nashville, TN (February 3, 2022) – Vesalio is pleased to announce the addition of Earl Slee as a board observer and senior advisor to the company, effective immediately.

Vesalio Announces Appointment of Mike Kujak as its New Independent Board...

Nashville, TN, January 19, 2022 – Vesalio is pleased to announce the appointment of Mike Kujak as chairman of its Board of Directors. In this role, Mike will bring expert knowledge and know-how from his years of leadership in the medical device start-up space.

Wallaby Medical launches Avenir® Coil System for hemorrhagic stroke trea...

SHANGHAI, CHINA – December 27, 2021 -  Wallaby Medical (“Wallaby”), a rapidly growing medical device company focused on developing and commercializing medical device products for treating stroke has partnered with Japan Lifeline Co., Ltd. (“JLL”), a publicly-listed medical device manufacturer and distributor with 48 sales offices across Japan, to bring Wallaby’s Japan PMDA approved Avenir® Coil System to the Japanese market. Avenir is used in the intravascular embolization of intracranial aneurysms and other neurovascular malformations (such as arteriovenous malformations and arteriovenous fistulas), as well as arterial and venous embolization of peripheral blood vessels.

Vesalio Initiates Clinical Study Evaluating Innovative Thrombectomy Tech...

NASHVILLE, Tenn., (December 23, 2021) – Today, Vesalio announced the start of enrollment in its NATURE study using enVast™, the company’s first thrombectomy system for patients presenting with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.

Largest real-world Flow Diverter study verifies safety and efficacy for...

November 16, 2021, Bochum, Germany. The authors of the Diversion-p64  study 1 conclude that phenox’ p64 Flow Modulation Device has a high efficacy and demonstrates one of the lowest rates of morbidity-mortality compared to similar studies. The trial represents the largest prospective study on flow diversion to date. With 420 patients enrolled in 26 centres across 10 countries, the results provide strong evidence for maximized flow modulation effect from the 64-wire braid design of the p64 device for treating intracranial aneurysms.

Phenox announces expansion of their technology portfolio for acute ische...

October 5, 2021, Bochum, Germany. Adding to their already extensive technology portfolio, phenox today announced the introduction of the pRESET® 6-50 mechanical thrombectomy device for the treatment of acute large vessel occlusive (LVO) stroke. This latest addition makes the pRESET 6-50 the longest stent retriever in the phenox portfolio and one of the longest stent retrievers available on the market for mechanical thrombectomy. Now offering a complete portfolio of 7 different sizes, phenox continues to demonstrate their ability to bring new devices to the market quickly in response to clinical evidence and market demands.